Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hierarchical diagnosis and treatment for somatic diseases with comorbid depression and anxiety
ChiCTR2400089174Phase 4Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of escitalopram, sertraline and bupropion in major depressive disorder (MDD) and anxiety disorder (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Hierarchical diagnostic and treatment technology. Started Sep 2024; status: completed.
02
Drugs
escitalopramsertralinebupropion
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2400089174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089174.